This record was last updated May 31, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-09-29; most recent amendment 2025-05-27.